Get started

Financials · SILO

Silo Pharma Inc. (SILO) financials

For the twelve months ended Jun 30, 2026, Silo Pharma Inc. reported $54.1K of revenue and -$4.47M of net income.

Revenue, TTM
$54.1K
Revenue growth, YoY
-25.0%
Net income, TTM
-$4.47M
Net margin
-8269.5%
Cash
$3.28M
P/S
57.37
Market cap
$3.1M
Annual revenue$72.1K
FY2019FY2025
Annual net income-$4.23M
FY2017FY2025

SILO revenue and earnings growth

SILO revenueQ2 2026$0

Quarter YoY
-100.0%
QoQ
-100.0%
FY YoY
+0.0%
5Y CAGR
+12.0%

SILO revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was $72.1K, up 0.0% from fiscal 2024. Compound annual growth was +12.0% over 5 years. It rose in 2 of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.

SILO net incomeQ2 2026-$832.8K

SILO net income was -$832.8K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.20M a year earlier. For the full fiscal 2025 it was -$4.23M, compared with -$4.39M in fiscal 2024.

SILO EPSQ2 2026-$0.76

SILO diluted EPS was -$0.76 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$7.50.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2013
Dec 31, 2013
Revenue$72.1K$72.1K$72.1K$72.1K$1.2K$40.9K$40.6K---
Cost of revenue$44.3K$5.8K$5.8K$5.8K$5.0K$176.1K$27.4K---
Gross profit$27.8K$66.3K$66.3K$66.3K$66.3K-$135.2K$13.2K---
Research and development$2.16M$2.37M$845.1K$1.29M$693.9K$26.3K----
Selling, general and admin--$390.1K$227.3K$163.0K$50.2K$87.0K$76.1K$29.6K$10.3K
Operating income-$4.28M-$4.71M-$3.86M-$3.63M-$2.74M-$2.20M-$930.4K-$594.2K-$490.9K-
Interest expense$37.3K$5.1K$4.9K$2.2K$3.0K$80$0---
Pre-tax income-$4.23M-$4.39M-$3.63M-$3.91M$4.18M-$2.67M----
Income tax----$24.9K-----
Net income-$4.23M-$4.39M-$3.70M-$3.91M$3.90M-$3.04M-$1.01M-$969.5K$356.5K-
EPS, basic-$7.50-$17.85-$18.00-$25.65$21.75-$0.75-$0.60-$0.30$0.15-
EPS, diluted-$7.50-$17.85-$18.00-$25.65$21.45-$0.75-$0.60-$0.30$0.15-
Diluted shares558,818.133245,359.267205,324.933152,282.667127,896.2674.4M1.6M3.3M3.5M-

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2013
Dec 31, 2013
Cash and equivalents$4.75M$3.91M$3.52M$11.37M$9.84M$1.13M$111.8K$336.7K$294.6K$2.01M
Short-term investments$2.11M$3.17M$4.14M-------
Receivables---$66.0K-$23.5K----
Inventory-----$33.5K$156.4K$27.0K--
Current assets$7.39M$7.11M$7.68M$11.57M$10.40M$1.43M$493.8K$626.0K$1.64M-
Total assets$7.61M$7.41M$7.75M$11.64M$10.49M$1.43M$493.8K$855.4K$1.64M$2.21M
Current liabilities$650.2K$1.66M$775.6K$436.3K$490.0K$141.7K$116.7K$48.0K$38.3K-
Total debt---------$15.0K
Total liabilities$1.30M$2.38M$1.57M$1.30M$1.43M$146.0K$116.7K--$18.7K
Shareholders' equity$6.31M$5.03M$6.18M$10.34M$9.06M$1.28M-$22.9K$407.4K$1.20M$1.79M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2013
Dec 31, 2013
Operating cash flow-$4.66M-$3.83M-$3.22M-$3.50M-$2.28M-$1.16M-$794.3K$272.6K-$284.6K-$181.6K
Investing cash flow$644.0K$973.8K-$4.15M$86.7K$7.19M$39.0K$186.7K-$250.0K--
Financing cash flow$4.86M$3.24M-$471.1K$4.94M$3.79M$2.13M$382.7K$19.5K-$2.19M
Stock-based compensation$117.0K$906.8K$871.6K$577.7K$395.1K$756.0K$319.6K$145.0K$177.5K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2013
Dec 31, 2013
Revenue growth, YoY0.0%0.0%0.0%5858.8%-97.0%0.9%----
Gross margin38.6%91.9%91.9%91.9%5476.0%-330.4%32.5%---
Operating margin-5937.0%-6526.4%-5347.4%-5031.3%-226805.2%-5380.2%-2293.4%---
Net margin-5863.5%-6092.6%-5132.6%-5420.9%322623.2%-7422.5%-2497.7%---
Return on equity-67.0%-87.3%-59.9%-37.8%43.1%-237.2%--237.9%29.6%-
Return on assets-55.6%-59.3%-47.8%-33.6%37.2%-212.9%-205.2%-113.3%21.7%-
Current ratio11.364.299.9026.5221.2310.074.2313.0542.81-
Debt to equity---------0.01

Source: XBRL data Silo Pharma Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Aug 13, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

SILO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
SILO$54.1K-25.0%-$4.47M-8269.5%$3.1M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

SILO FAQ

7 questions
  • What is SILO revenue?
    Silo Pharma Inc. (SILO) reported $54.1K of revenue for the twelve months ended Jun 30, 2026. That is down 25.0% from the year before. Revenue for fiscal 2025 was $72.1K.
  • Is SILO profitable?
    No. Silo Pharma Inc. reported a net loss of $4.47M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does SILO have?
    Silo Pharma Inc. reported $3.28M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is SILO revenue growing?
    Silo Pharma Inc.'s revenue changed +0.0% in fiscal 2025, to $72.1K. Its compound annual growth rate was +12.0% over 5 years.
  • What is SILO gross margin?
    Silo Pharma Inc.'s gross profit was -$8.0K on $54.1K of revenue for the twelve months ended Jun 30, 2026, a gross margin of -14.8%.
  • When did SILO last report financial results?
    The latest statements here come from Silo Pharma Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this SILO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Silo Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.